因此，惟亚德生物团队利用重组溶瘤病毒在TME所高效表达的特异性蛋白，来纠正脂质紊乱并抑制促肿瘤炎症。目前首个管线产品重组NV-A01腺病毒注射液针对三阴乳腺癌、晚期肝癌及其他恶性实体肿瘤的适应症已进入Ⅰ期临床试验；与此同时，团队完成了在复发的高级别脑 ...

Oncolytics Biotech is seeking accelerated approval for its lead cancer therapy, pelareorep, with plans to start a ...

Moreover, TILT’s oncolytic viruses encoding a variety of cytokines can be delivered either directly to tumors or intravenously, and have applicability across a wide range of cancer indications.

Virus is associated with sickness, but oncolytic virus therapies, which harness viruses to attack and kill cancer cells, may soon change the standard of treatment for cancer, including those long ...

Transgene’s therapeutic vaccine candidate TG4001 has flunked a phase 2 solid tumor trial. But, while the prospect failed to ...

Oncolytic virus therapy is not a new discovery, but it may now be positioned as the next major breakthrough in cancer treatment following the success of checkpoint inhibitors in immunotherapy.

KaliVir Immunotherapeutics has dosed the first subject in a Phase I/Ib clinical trial for its new oncolytic immunotherapy, ...

Johnson & Johnson has bought oncolytic immunotherapy biotech BeneVir, adding immune-oncology drugs to a cancer pipeline dominated by antibodies and small molecules. Benevir uses proprietary ...

CLD-101 is a novel stem cell-based treatment that delivers oncolytic viruses to tumors, which may benefit patients with newly ...

WOBURN, Mass., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today ...